Hans Schambye
Chief Executive Officer bei GALECTO, INC.
Vermögen: 40 894 $ am 31.03.2024
Profil
Hans Thalsgård Schambye is the founder of Profound Pharma AS (founded in 1999), OncoNOx ApS (founded in 2011), Galecto Biotech ApS (founded in 2011), and Galecto, Inc. (founded in 2011).
He is currently the Chairman of Dansk Biotek.
In the past, he held positions such as Chief Executive Officer at Rose Pharma A (2004-2006) and Recepticon ApS (2006-2009), Director-Biology & Pharmacology at Maxygen, Inc. (1999-2003), and Project Manager at Novo Nordisk A.
He also served as Chairman at Nanoference ApS and IO Biotech ApS, and as a Director at Forward Pharma A.
Dr. Schambye has a doctorate degree from the University of Copenhagen and the University of Southern Denmark.
Bekannte Unternehmensbeteiligungen
Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
---|---|---|---|---|
GALECTO, INC.
0,19% | 03.01.2024 | 52 428 ( 0,19% ) | 40 894 $ | 31.03.2024 |
Aktive Positionen von Hans Schambye
Unternehmen | Position | Beginn |
---|---|---|
GALECTO, INC. | Chief Executive Officer | 01.11.2011 |
Dansk Biotek
Dansk Biotek Miscellaneous Commercial ServicesCommercial Services Dansk Biotek is an industry association for biotech companies with promoting the biotechnological research, development and production in taking care of corporate interests in this regard, both nationally and internationally. The company was founded in 1987 and is headquartered in Copenhagen, Denmark. | Chairman | - |
Galecto Biotech ApS
Galecto Biotech ApS Pharmaceuticals: MajorHealth Technology Galecto Biotech ApS provides galectin modulators for the treatment of severe diseases, including fibrosis and cancer. Its products include galectin-3 inhibitors, fibrosis and literature. The company was founded by Tariq Sethi, Hans Thalsgard Schambye, Ulf Jorgen Nilsson, and Hakon Leffler in 2011 and is headquartered in Copenhagen, Denmark. | Chief Executive Officer | 01.01.2011 |
Ehemalige bekannte Positionen von Hans Schambye
Unternehmen | Position | Ende |
---|---|---|
Recepticon ApS
Recepticon ApS Pharmaceuticals: MajorHealth Technology ReceptIcon is a biotech company based on the identification of novel receptors in the kidney that are responsible for renal uptake and nephrotoxity of therapeutic drugs. The company is focused on the development of receptor antagonists that prevent accumulation of therapeutics in the kidney. Such antagonists can be used as active pharmaceutical ingredients for reformulation of marketed nephrotoxic drugs thereby precluding their toxic side effects. | Chief Executive Officer | 01.11.2009 |
Rose Pharma A/S
Rose Pharma A/S Pharmaceuticals: MajorHealth Technology Rose Pharma A/S provides pharmaceutical products for treatment of pain in connection with irritable bowel syndrome. It develops treatments for irritable bowel syndrome (IBS) and functional dyspepsia, and disorders. The firm focuses on the medical applications of gastrointestinal hormones. The company was founded in 2003 and is headquartered in Roskilde, Denmark. | Chief Executive Officer | 01.08.2006 |
Maxygen, Inc.
Maxygen, Inc. Miscellaneous Commercial ServicesCommercial Services Maxygen, Inc. is a biotechnology company. It is focused on the potential further development of its MAXY-G34 product, a next-generation pegylated, granulocyte colony stimulating factor, G-CSF, for the treatment of chemotherapy induced neutropenia and acute radiation syndrome. G-CSF is a natural protein that functions by stimulating the body's bone marrow to produce more white blood cells. The company was founded on May 7, 1996 and is headquartered in San Mateo, CA. | Corporate Officer/Principal | 01.12.2003 |
Profound Pharma AS
Profound Pharma AS Pharmaceuticals: MajorHealth Technology Profound Pharma AS provides pharmaceutical products. The Danish company was founded by Jan Møller Mikkelsen, Anders H. Pedersen, Hans Thalsgård Schambye. Profound Pharma was acquired by Maxygen, Inc. on August 10, 2000 for $69.46 million. | Founder | 01.01.2000 |
FORWARD PHARMA A/S | Director/Board Member | - |
Ausbildung von Hans Schambye
University of Copenhagen | Doctorate Degree |
University of Southern Denmark | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 2 |
---|---|
NOVO NORDISK A/S | Health Technology |
GALECTO, INC. | Health Technology |
Private Unternehmen | 11 |
---|---|
Maxygen, Inc.
Maxygen, Inc. Miscellaneous Commercial ServicesCommercial Services Maxygen, Inc. is a biotechnology company. It is focused on the potential further development of its MAXY-G34 product, a next-generation pegylated, granulocyte colony stimulating factor, G-CSF, for the treatment of chemotherapy induced neutropenia and acute radiation syndrome. G-CSF is a natural protein that functions by stimulating the body's bone marrow to produce more white blood cells. The company was founded on May 7, 1996 and is headquartered in San Mateo, CA. | Commercial Services |
Profound Pharma AS
Profound Pharma AS Pharmaceuticals: MajorHealth Technology Profound Pharma AS provides pharmaceutical products. The Danish company was founded by Jan Møller Mikkelsen, Anders H. Pedersen, Hans Thalsgård Schambye. Profound Pharma was acquired by Maxygen, Inc. on August 10, 2000 for $69.46 million. | Health Technology |
Rose Pharma A/S
Rose Pharma A/S Pharmaceuticals: MajorHealth Technology Rose Pharma A/S provides pharmaceutical products for treatment of pain in connection with irritable bowel syndrome. It develops treatments for irritable bowel syndrome (IBS) and functional dyspepsia, and disorders. The firm focuses on the medical applications of gastrointestinal hormones. The company was founded in 2003 and is headquartered in Roskilde, Denmark. | Health Technology |
Recepticon ApS
Recepticon ApS Pharmaceuticals: MajorHealth Technology ReceptIcon is a biotech company based on the identification of novel receptors in the kidney that are responsible for renal uptake and nephrotoxity of therapeutic drugs. The company is focused on the development of receptor antagonists that prevent accumulation of therapeutics in the kidney. Such antagonists can be used as active pharmaceutical ingredients for reformulation of marketed nephrotoxic drugs thereby precluding their toxic side effects. | Health Technology |
Forward Pharma A/S
Forward Pharma A/S Pharmaceuticals: MajorHealth Technology Forward Pharma A/S is a biopharmaceutical company, which engages in the research and development of medicinal treatment for inflammatory and neurological indications. It focuses on the immunomodulatory compound dimethyl fumarate and its derivatives. The company was founded by Florian Schönharting on July 2005 and is headquartered in Copenhagen, Denmark. | Health Technology |
Dansk Biotek
Dansk Biotek Miscellaneous Commercial ServicesCommercial Services Dansk Biotek is an industry association for biotech companies with promoting the biotechnological research, development and production in taking care of corporate interests in this regard, both nationally and internationally. The company was founded in 1987 and is headquartered in Copenhagen, Denmark. | Commercial Services |
Nanoference ApS
Nanoference ApS Pharmaceuticals: MajorHealth Technology Nanoference ApS is a holding company that manufactures medicine for the treatment of infectious pulmonary diseases. It develops a technology that uses nanoparticles to deliver so-called Small interfering ribonucleic acid (siRNA) molecules directly to the desired location in the body. Its nano particles composed of the sugar substance chitosan. Its RNA has the ability to identify cells and shut down certain disease genes. The company was founded by Kenneth Alan Howard, Jørgen Kjems, and Flemming Besenbacher in March 2010 and is headquartered in Aarhus, Denmark. | Health Technology |
OncoNOx ApS
OncoNOx ApS Pharmaceuticals: MajorHealth Technology OncoNOx ApS provides drugs for the treatment of autoimmune diseases and cancer. It is a pharmaceutical company that transforms marketed drugs into proprietary molecules with anti-cancer and/or anti-inflammatory properties. The firm's projects include OX1001 and OX27-NO is a potent anti-cancer compounds in vitro and in vivo and are intended for the treatment of cancer, and OX1001 also exhibits anti-viral activity and is in development for treatment of human immunodeficiency virus (HIV) and acquired immune deficiency syndrome patients with or without HIV related cancer. The company was founded by Ferdinando Nicoletti, Gianni Garotta, Yousef Al-Abed, Marco Donia, and Mai-Britt Zocca in 2011 and is headquartered in Copenhagen, Denmark. | Health Technology |
Galecto Biotech ApS
Galecto Biotech ApS Pharmaceuticals: MajorHealth Technology Galecto Biotech ApS provides galectin modulators for the treatment of severe diseases, including fibrosis and cancer. Its products include galectin-3 inhibitors, fibrosis and literature. The company was founded by Tariq Sethi, Hans Thalsgard Schambye, Ulf Jorgen Nilsson, and Hakon Leffler in 2011 and is headquartered in Copenhagen, Denmark. | Health Technology |
IO Biotech ApS
IO Biotech ApS BiotechnologyHealth Technology IO Biotech ApS operates as a clinical stage biotech company. It develops immunotherapy for cancer by targeting a mechanism used by tumour cells to evade immune responses. The company was founded by Mai-Britt Zocca, Mads Hald Andersen, Inge Marie Svane, Anders Ljungqvist and Per Thor Straten and is headquartered in Copenhagen, Denmark. | Health Technology |
Step Pharma SAS
Step Pharma SAS Pharmaceuticals: MajorHealth Technology Step Pharma SAS develops drugs for immunosuppressive therapies. The company was founded by Geoffroy de Ribains, Alain Fischer, and Sylvain Latour and is headquartered in Paris, France. | Health Technology |